Is There a Generic Version of Dupixent in 2026?
No, no generic version of Dupixent (dupilumab) will be available in 2026. Dupixent is a biologic monoclonal antibody, so generics aren't possible—instead, biosimilars (similar but not identical copies) would compete after patents expire. Key U.S. patents protecting Dupixent extend beyond 2026, blocking any biosimilar entry that year.[1][2]
When Do Dupixent Patents Expire?
Primary U.S. composition-of-matter patents for Dupixent expire in 2031, with method-of-use and formulation patents lasting until 2033–2038. Pediatric exclusivity could push this to 2034. No major patents lapse in 2026.[2]
Link to patent details: DrugPatentWatch.com - Dupixent Patents
Are Biosimilars in the Pipeline for 2026?
No approved or pending biosimilars target a 2026 U.S. launch. Companies like Alvotech, Intas, and Celltrion have filed abbreviated biologics license applications (aBLAs), but FDA reviews and patent challenges delay launches until at least 2031–2032. European biosimilars (e.g., from Biocon and Lupin) launched in 2025, but U.S. entry faces separate patent litigation.[1][2][3]
Why Is Dupixent Still Protected in 2026?
Sanofi and Regeneron hold over 20 Orange Book-listed patents, including formulation patents extended via pediatric studies. Ongoing lawsuits, like those against Samsung Bioepis, reinforce exclusivity. Dupixent generated $12.7 billion in 2024 sales, fueling aggressive defense.[2][4]
What Happens If Patents Are Challenged Successfully?
Biosimilar makers can challenge via FDA's 351(k) pathway, but settlements often delay entry (e.g., 2031 carve-outs). A rare early win could allow limited U.S. launch pre-2031, but no such rulings exist for Dupixent as of 2025.[2]
Dupixent Price and Cost-Saving Alternatives Before Biosimilars
Annual U.S. list price exceeds $40,000 per patient. No generics or biosimilars mean high costs through 2030. Patient assistance programs from Sanofi cover copays for eligible insured patients. Off-label alternatives like JAK inhibitors (e.g., generic tofacitinib) treat some indications cheaper but lack direct comparability.[4]
Sources
[1]: FDA Purple Book - Dupilumab
[2]: DrugPatentWatch.com - Dupixent
[3]: EMA Approvals - Dupixent Biosimilars
[4]: Regeneron Q4 2024 Earnings